Thailand Single-Use Bio-Processing Systems Market Size and Forecast 2032

Market Overview

Thailand Single-Use Bio-Processing Systems market size was valued at USD 62.03 million in 2024 and is anticipated to reach USD 214.11 million by 2032, at a CAGR of 16.75% during the forecast period (2024-2032).

The Thailand Single-Use Bio-Processing Systems market is experiencing robust growth, driven by the increasing adoption of single-use technologies in biopharmaceutical manufacturing due to their cost-efficiency, reduced risk of cross-contamination, and faster turnaround times. Rising investments in the biotechnology and life sciences sectors, along with supportive government initiatives to enhance healthcare infrastructure, further propel market expansion. Additionally, the growing demand for flexible and scalable production solutions in biologics and vaccine development reinforces the shift from traditional stainless-steel systems to disposable bioprocessing systems. Technological advancements, such as improvements in film materials and automation capabilities, are enhancing the performance and reliability of single-use systems, making them more attractive to both established pharmaceutical companies and emerging biotech firms. Moreover, the ongoing focus on environmental sustainability and waste reduction aligns with the adoption of these systems, encouraging broader market penetration. These trends collectively position Thailand as a key emerging market for single-use bioprocessing solutions in the Asia-Pacific region.

The geographical landscape of Thailand's Single-Use Bio-Processing Systems market is shaped by the concentration of biopharmaceutical activities in key regions such as Bangkok, the Eastern Economic Corridor (EEC), Chiang Mai, and Southern Thailand. Bangkok and the EEC serve as central hubs for large-scale manufacturing and research, benefiting from advanced infrastructure, skilled labor, and government support. Chiang Mai and Southern Thailand are emerging regions, contributing through academic research and smaller-scale development initiatives. The market features a mix of global and regional players driving technological advancement and system integration. Key participants include Wuxi AppTec, Cytiva, Thermo Fisher Scientific Asia, Merck Life Science, FUJIFILM Irvine Scientific, and Danaher Asia-Pacific. These companies are actively expanding their footprint through strategic partnerships, product innovation, and localization efforts. Additionally, local institutions and biotech startups are increasingly collaborating with these global leaders, creating a dynamic and competitive environment that supports the growth of single-use technologies across the Thai bioprocessing ecosystem.

Market Insights

• The Thailand Single-Use Bio-Processing Systems market was valued at USD 62.03 million in 2024 and is expected to reach USD 214.11 million by 2032, growing at a CAGR of 16.75% from 2024 to 2032.

• The global single-use bio-processing systems market was valued at USD 17,326.05 million in 2024 and is projected to reach USD 57,663.39 million by 2032, growing at a CAGR of 16.22% from 2024 to 2032.

• The growing biopharmaceutical industry and increased demand for biologics are major drivers of market growth.
• Technological advancements in automation and smart systems are driving innovation in single-use technologies.
• Increasing adoption of single-use systems by contract manufacturing organizations (CMOs) and biotech startups boosts market demand.
• Supply chain challenges and high initial costs of single-use systems pose key market restraints.
• The market is highly competitive with global players like Wuxi AppTec, Cytiva, and Thermo Fisher Scientific Asia leading the way.
• Regional growth is strongest in Bangkok and the Eastern Economic Corridor (EEC), with smaller contributions from Chiang Mai and Southern Thailand.

Report Scope

This report segments the Thailand Single-Use Bio-Processing Systems Market as follows:

Market Drivers

Growing Biopharmaceutical Industry and Demand for Efficient Manufacturing

Thailand’s rapidly expanding biopharmaceutical industry is a primary driver for the growth of single-use bio-processing systems. As demand for biologics, including monoclonal antibodies, vaccines, and cell and gene therapies, continues to rise, pharmaceutical companies are seeking cost-effective, flexible, and scalable manufacturing solutions. For instance, the Thailand Board of Investment (BOI) has introduced investment incentives to support the expansion of biopharmaceutical manufacturing, encouraging the adoption of advanced technologies like single-use systems. Single-use technologies significantly reduce capital investment and operational costs associated with traditional stainless-steel systems, such as cleaning validation and sterilization. This makes them particularly attractive to emerging biotechs and contract manufacturing organizations (CMOs) operating within Thailand’s growing life sciences ecosystem.

Government Support and Healthcare Infrastructure Development

Government initiatives aimed at strengthening the country's healthcare and biopharmaceutical capabilities are also driving the adoption of single-use systems. Thailand’s strategic plans, such as the “Thailand 4.0” policy, emphasize innovation-driven growth, particularly in high-value sectors like biotechnology. For instance, the Thai government has allocated over 1.7 billion baht to support medical industry development, including biopharmaceutical innovation and infrastructure improvements. Incentives, funding programs, and partnerships with international players are encouraging domestic production of biologics and vaccines. Additionally, the government’s efforts to enhance healthcare infrastructure and preparedness for pandemics and future health emergencies have increased the demand for advanced and rapid bioprocessing technologies, further boosting market adoption.

Technological Advancements in Single-Use Systems

Technological innovation in single-use bio-processing components, such as bioreactors, mixers, tubing, connectors, and sensors, is significantly enhancing their performance, reliability, and acceptance across the Thai pharmaceutical landscape. Improvements in materials science have led to more robust, chemically resistant, and extractable-free films, addressing safety and regulatory concerns. Meanwhile, automation and integration capabilities are enabling better process control and real-time monitoring, which are critical for maintaining product quality in biologics manufacturing. These technological advancements make single-use systems not only more efficient but also more compliant with international GMP standards, encouraging their uptake in both domestic and export-focused production facilities.

Focus on Flexibility, Speed, and Environmental Sustainability

In today’s fast-evolving healthcare market, flexibility and speed are essential. Single-use systems allow for quicker batch changes, faster scale-up or scale-down, and streamlined facility design. These features are particularly beneficial for Thailand’s small- and medium-sized enterprises (SMEs) entering the biologics space. Additionally, the reduced need for water and cleaning chemicals in single-use systems aligns with Thailand’s increasing environmental and sustainability goals. The lower carbon footprint and waste management improvements offered by these systems appeal to both manufacturers and regulators focused on green manufacturing practices. As sustainability becomes a competitive differentiator, single-use systems are emerging as a strategic choice in Thailand’s bio-manufacturing sector.

Market Trends

Rising Adoption of Single-Use Systems Across Biotech Startups and CMOs

A key trend in Thailand’s single-use bio-processing systems market is the increasing adoption among biotech startups and contract manufacturing organizations (CMOs). These entities are opting for single-use technologies due to their lower initial capital requirements, faster setup times, and ease of scalability. This shift supports agile production models, particularly important in the dynamic and innovation-driven biologics sector. As new entrants continue to emerge in Thailand’s biopharmaceutical landscape, single-use systems offer an ideal solution for pilot-scale production and clinical manufacturing, fostering broader industry participation.

Focus on Local Manufacturing and Supply Chain Resilience

Another notable trend is the emphasis on developing local manufacturing capabilities and strengthening supply chain resilience. The global disruptions experienced during the pandemic underscored the importance of having a reliable domestic supply of critical bioprocessing components. For instance, the Thailand Development Research Institute (TDRI) has emphasized the need for strengthening Thailand’s supply chain resilience through local production and partnerships. In response, Thailand is encouraging local production of single-use consumables and working to build partnerships with regional suppliers. This trend not only reduces dependency on imports but also promotes faster lead times and better customization for local market needs. As Thailand positions itself as a regional biomanufacturing hub, the localization of single-use systems is expected to become a strategic priority.

Expansion of Biologics and Vaccine Manufacturing Capabilities

Thailand is experiencing a growing focus on biologics and vaccine production, which directly influences the demand for single-use systems. The COVID-19 pandemic highlighted the need for fast and flexible manufacturing infrastructure, pushing several local and international players to invest in vaccine production facilities within the country. For instance, SK bioscience has signed a Memorandum of Understanding with Thailand’s Government Pharmaceutical Organization (GPO) to strengthen vaccine infrastructure and localize vaccine manufacturing. Single-use technologies, known for their adaptability and rapid deployment, are becoming integral to this expansion. Their use in producing viral vectors, mRNA-based products, and recombinant proteins further solidifies their role in Thailand’s evolving life sciences manufacturing environment.

Integration of Automation and Smart Bioprocessing Technologies

The integration of automation and smart technologies into single-use systems is transforming the Thai bio-processing landscape. Real-time monitoring tools, single-use sensors, and process analytical technologies (PAT) are being embedded into these systems to enhance process control, improve product consistency, and meet stringent regulatory requirements. This trend is aligned with Thailand’s push toward Industry 4.0, where digitalization and automation are central themes. As biomanufacturers prioritize data integrity and operational efficiency, the adoption of intelligent single-use systems is gaining traction across the market.

Market Challenges Analysis

High Initial Cost and Limited Technical Expertise

Despite their long-term cost benefits, the high upfront investment in single-use bio-processing systems can be a significant barrier, especially for small and medium-sized enterprises (SMEs) in Thailand. Many local manufacturers remain cautious due to the perceived financial risk associated with switching from traditional stainless-steel systems to newer disposable technologies. For instance, the Asian Journal of Hospital Pharmacy highlights that the lack of technical expertise in single-use bioprocessing remains a challenge, necessitating investment in workforce training. Additionally, while single-use systems simplify many aspects of bioprocessing, they also require specialized technical knowledge for integration, validation, and troubleshooting. A limited pool of skilled professionals trained in single-use technology and bioprocess automation in the Thai workforce further constrains widespread adoption. This skills gap necessitates substantial investment in training and education, which can slow down implementation timelines and increase operational risk for new users.

Supply Chain Dependencies and Regulatory Hurdles

Another major challenge lies in the dependency on global suppliers for critical single-use components such as bioreactor bags, tubing, filters, and sensors. Fluctuations in global supply chains, particularly during periods of geopolitical tension or pandemics, can lead to delays, cost fluctuations, and availability issues in the Thai market. This reliance not only affects operational continuity but also limits customization and responsiveness to local needs. Additionally, navigating complex and evolving regulatory frameworks presents a challenge for both domestic manufacturers and international suppliers entering the Thai market. Compliance with global Good Manufacturing Practice (GMP) standards and local regulatory requirements demands significant documentation, validation, and quality assurance, adding further layers of complexity and cost. These supply chain and regulatory challenges pose considerable obstacles to the consistent and scalable deployment of single-use bio-processing systems in Thailand.

Market Opportunities

Thailand's single-use bio-processing systems market presents substantial opportunities, fueled by the country's strategic ambition to become a regional biotechnology and pharmaceutical manufacturing hub. The rising demand for biologics, cell therapies, and personalized medicine across Southeast Asia positions Thailand as an attractive base for regional production and export. As global pharmaceutical companies seek to diversify their manufacturing footprints, Thailand’s favorable investment climate, cost competitiveness, and improving regulatory landscape offer compelling advantages. Local biopharmaceutical companies are increasingly adopting flexible manufacturing models, and single-use systems provide a scalable, cost-effective solution that aligns well with these evolving needs. Additionally, the Thai government’s continued support through policies like “Thailand 4.0” and incentives for biotech investments enhances the growth potential for this market segment.

Opportunities also lie in the development of localized supply chains and technical expertise to support the growing adoption of disposable technologies. Domestic manufacturing of single-use components, supported by partnerships with international technology providers, can help reduce reliance on imports and improve supply chain resilience. There is also growing demand for integrated, automated single-use systems that incorporate real-time analytics and process control areas where technology providers can offer significant value. Furthermore, academic and research institutions in Thailand are increasing their involvement in bioprocess development, creating additional demand for pilot-scale and research-grade single-use systems. As Thailand expands its footprint in biologics, biosimilars, and vaccine production, suppliers and service providers that can deliver customized, GMP-compliant, and scalable single-use solutions will find a receptive and growing market. Overall, Thailand presents a dynamic landscape of opportunities for stakeholders willing to invest in innovation, training, and strategic partnerships within the single-use bioprocessing ecosystem.

Market Segmentation Analysis:

By Type:

The Thailand Single-Use Bio-Processing Systems market is segmented by type into Single-Use Bioreactors, Single-Use Mixers, Single-Use Bags, Single-Use Connectors, and Others. Among these, Single-Use Bioreactors represent the dominant segment, driven by their widespread application in both upstream and downstream bioprocessing. Their ability to support high-density cell cultures while maintaining sterility and reducing contamination risks makes them highly attractive for biologics production. Single-Use Bags also hold a significant market share due to their extensive use in media storage, sampling, and transport. These bags offer flexibility, reduce cleaning time, and enhance process efficiency, especially in multi-product facilities. Single-Use Mixers are gaining traction, particularly in process development and small-scale commercial batches, where consistent mixing and closed systems are essential. Single-Use Connectors support modular system design and ease of assembly, further driving adoption in dynamic production environments. The "Others" category, which includes filters, sensors, and tubing, is also growing, as process complexity and system integration needs continue to evolve across the industry.

By Application:

Based on application, the Thailand market is segmented into Research & Development, Manufacturing, Process Development, Commercial Production, and Others. Manufacturing leads this segment, driven by the rising adoption of single-use systems in full-scale biologics and vaccine production facilities. These systems offer operational agility, faster turnaround times, and reduced contamination risks critical factors in commercial-scale operations. Process Development is another growing area, as companies increasingly leverage disposable systems for pilot-scale testing and optimization of production protocols. In Research & Development, academic institutions and biotech startups use single-use systems to accelerate innovation and reduce infrastructure costs. Commercial Production is expanding steadily, particularly with the increased focus on biosimilars and personalized medicine in Thailand. The "Others" segment includes niche applications such as diagnostics and veterinary biologics, contributing to the broader adoption of these systems. Across all segments, the versatility, cost efficiency, and regulatory alignment of single-use technologies continue to support their strong growth trajectory in Thailand’s life sciences sector.

Segments:

Based on Type:

• Single-Use Bioreactors
• Single-Use Mixers
• Single-Use Bags
• Single-Use Connectors
• Others

Based on Application:

• Research & Development
• Manufacturing
• Process Development
• Commercial Production
• Others

Based on End- User:

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Contract Manufacturing Organizations (CMOs)
• Others

Based on the Geography:

• Bangkok
• Eastern Economic Corridor (EEC)
• Chiang Mai
• Southern Thailand

Regional Analysis

Bangkok

Bangkok holds the largest market share in Thailand’s single-use bio-processing systems market, accounting for approximately 42% of the national revenue. As the country's capital and primary hub for healthcare, pharmaceuticals, and biotechnology research, Bangkok houses the highest concentration of hospitals, research institutions, and biopharmaceutical companies. The presence of world-class medical universities and government-funded innovation centers has accelerated R&D in biologics and advanced therapies, fueling the adoption of single-use systems in pilot and clinical-scale production. Additionally, several contract manufacturing organizations (CMOs) and multinational pharmaceutical companies have established their Thai operations in the Bangkok metropolitan area, leveraging the city's infrastructure and skilled labor force. As innovation accelerates and demand for flexible manufacturing increases, Bangkok is expected to maintain its leadership position in the coming years.

Eastern Economic Corridor (EEC)

The Eastern Economic Corridor (EEC) region contributes around 33% of the market share, driven by targeted government investment and its positioning as a strategic industrial and biotech manufacturing zone. Comprising Chonburi, Rayong, and Chachoengsao provinces, the EEC is at the heart of Thailand’s “Thailand 4.0” initiative, which promotes high-tech and high-value industries, including biopharmaceuticals. Major investments in industrial biotech parks, tax incentives for foreign direct investment (FDI), and partnerships with global technology providers have made the EEC a focal point for modern, large-scale bioprocessing facilities. The demand for single-use systems in this region is primarily led by full-scale manufacturing and commercial production facilities seeking scalable, cost-effective, and GMP-compliant production methods. The EEC is poised to become a regional hub for biopharmaceutical exports, further driving demand for advanced processing technologies.

Chiang Mai

Chiang Mai represents approximately 15% of the market share, emerging as a growing center for research, academic collaboration, and medical innovation in Northern Thailand. The region hosts several prominent universities and medical schools that are increasingly involved in biologics research, clinical trials, and early-phase drug development. Single-use systems are primarily adopted here for research and process development, enabling fast prototyping and flexible experimentation. Chiang Mai’s health-tech startups and incubators also contribute to the regional demand for small-scale, disposable bioprocessing tools. Though smaller in scale compared to Bangkok and the EEC, Chiang Mai’s emphasis on innovation and education provides a foundation for long-term growth in this segment.

Southern Thailand

Southern Thailand holds a modest 10% market share, with adoption centered around university-affiliated research centers and emerging pharmaceutical ventures. While the region does not yet host major biomanufacturing clusters, it benefits from government initiatives aimed at decentralizing industrial development and promoting medical tourism. Single-use systems in Southern Thailand are currently used in R&D and limited-scale therapeutic production, with potential for expansion as infrastructure and regional collaborations grow. With improved logistics and training initiatives, Southern Thailand may gradually increase its market footprint within the national bio-processing ecosystem.

Key Player Analysis

• Wuxi AppTec
• Shanghai Bailun Biotechnology Co., Ltd.
• Tsinghua University Suzhou Institute for Biomedicine
• FUJIFILM Irvine Scientific
• Cytiva
• Hitachi Chemical Co., Ltd.
• Mitsubishi Gas Chemical Company, Inc.
• Merck Life Science
• Thermo Fisher Scientific Asia
• Danaher Asia-Pacific

Competitive Analysis

The competitive landscape of Thailand's Single-Use Bio-Processing Systems market is characterized by the presence of both global leaders and regional players, contributing to innovation, technological advancements, and market expansion. Key players in this space include Wuxi AppTec, Shanghai Bailun Biotechnology Co., Ltd., Tsinghua University Suzhou Institute for Biomedicine, FUJIFILM Irvine Scientific, Cytiva, Hitachi Chemical Co., Ltd., Mitsubishi Gas Chemical Company, Inc., Merck Life Science, Thermo Fisher Scientific Asia, and Danaher Asia-Pacific. These companies have established a strong foothold in the Thai market through strategic partnerships, local collaborations, and an extensive product portfolio that spans single-use bioreactors, mixers, bags, connectors, and other essential bioprocessing components. These companies often focus on delivering high-performance systems that enhance scalability, flexibility, and cost-effectiveness, making them attractive to contract manufacturing organizations (CMOs) and biopharmaceutical companies. Regional players, on the other hand, are increasingly capitalizing on the growing demand by offering customized solutions that cater to local market needs and preferences. These players often benefit from lower operational costs, closer relationships with domestic clients, and better insight into local regulatory requirements. As the market continues to expand, competition is expected to intensify with an increased focus on innovation, product differentiation, and technology integration. Companies are increasingly investing in automation, real-time monitoring, and smart technologies, which are becoming key differentiators in a market that values efficiency, quality control, and regulatory compliance. The competitive environment is further shaped by collaborations, partnerships, and the growing trend of companies localizing their operations to strengthen supply chains and enhance responsiveness to the Thai market's evolving demands.

Recent Developments

• In April 2025, Thermo Fisher Scientific launched the 5L DynaDrive Single-Use Bioreactor, a bench-scale system designed for seamless scalability from 1 to 5,000 liters. This new bioreactor offers a 27% productivity increase over glass bioreactors, enhanced sustainability with biobased films, and consistent performance across different scales, supporting both large and small biopharma manufacturers. The DynaDrive S.U.B. supports robust production across scales and has the flexibility to accommodate a variety of cell lines and processing modalities.
• In April 2025, Sartorius Stedim Biotech entered a strategic partnership with Tulip Interfaces to drive digital transformation in single-use bioprocessing. The collaboration introduced Biobrain® Operate powered by Tulip, a suite of digital manufacturing applications that integrate with Sartorius equipment to reduce process variability, digitize operations, and ensure regulatory compliance. This partnership aims to advance paperless manufacturing and optimize resource efficiency in bioprocessing.
• In March 2025, Corning introduced new technologies to support advanced therapy applications, including the Ascent™ Fixed Bed Reactor (FBR) and expanded cell expansion platforms like HYPERStack®, HYPERFlask®, and CellSTACK®. These platforms feature closed systems and automation to reduce contamination risk and enhance scalability for bioprocess applications.
• In April 2023, Merck KGaA launched the Ultimus® Single-Use Process Container Film, featuring ten times greater abrasion resistance than other films, improved durability, and leak resistance for single-use assemblies. The technology is now available in Mobius® 3D process containers, enhancing operational efficiency and cell growth performance.

Market Concentration & Characteristics

The market concentration of Thailand's Single-Use Bio-Processing Systems is relatively moderate, with a mix of dominant global players and emerging regional companies. Large multinational corporations with established brands hold significant market share due to their advanced technological offerings, extensive product portfolios, and global supply chains. These companies focus on innovation, providing scalable and cost-effective solutions that cater to the growing demand in biopharmaceutical production. Meanwhile, regional players are gaining ground by offering more tailored solutions that meet the specific needs of Thailand’s local market, such as cost-effective, flexible systems and quick integration with existing infrastructures. The market characteristics are defined by rapid technological advancements, including automation, smart systems, and real-time monitoring, which are key to improving production efficiency and compliance with stringent regulations. As the demand for biologics, biosimilars, and vaccines increases, the competition will intensify, driving continuous innovation and further shaping the market landscape.

Report Coverage

The research report offers an in-depth analysis based on Type, Application, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. Thailand's single-use bioprocessing market is projected to experience significant growth, driven by increasing demand for biologics and biosimilars.
2. The adoption of single-use systems is expected to enhance production flexibility and reduce contamination risks in biopharmaceutical manufacturing.
3. Technological advancements, such as automation and real-time monitoring, are anticipated to improve process efficiency and scalability.
4. Government initiatives and investments in the biotechnology sector are likely to support the expansion of single-use bioprocessing systems.
5. Regional collaborations and partnerships are expected to foster innovation and knowledge sharing in the bioprocessing industry.
6. The development of local manufacturing capabilities for single-use components may reduce supply chain dependencies and costs.
7. Training programs and educational initiatives are anticipated to address the skills gap in operating advanced bioprocessing technologies.
8. Standardization efforts are expected to enhance compatibility and integration of single-use systems across different platforms.
9. The increasing focus on personalized medicine is likely to drive demand for flexible and scalable bioprocessing solutions.
10. The market is expected to witness intensified competition, leading to continuous innovation and improved product offerings.